Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X
The financing was co-led by Omega Funds and TCG X.
- The financing was co-led by Omega Funds and TCG X.
- In connection with the close of the Series C financing, Michelle Doig, Partner, Head of Corporate Development, Omega Funds and Chen Yu, Founding Managing Partner, TCG X, will join Artios Board of Directors.
- Michelle Doig, Partner, Head of Corporate Development, Omega Funds, said: Artios deep expertise in DNA damage response and novel approach to drive the search for new and better cancer treatments is an ideal match for Omega Funds.
- This financing follows an $84 million (65 million) Series B fundraise concluded in August 2018 and yields total capital raised to date from investors and strategic partners of more than US$320 million.